The Fogarty Institute continues to build its bench strength with the recent hire of seasoned medtech leader Marga Ortigas-Wedekind as chief commercial strategy officer. With 30 years of experience in medical and health technology companies at a variety of stages of development, her expertise will make her an asset to the entire team, most notably to our entrepreneurs,
As the Fogarty Institute continues to strengthen services to its companies-in-residence in areas critical to their growth and success, Craig Straley has joined as the director of clinical and regulatory affairs, bringing more than 20 years of experience in conducting clinical research with a number of successful startups.
As the Fogarty Institute continues to expand the services it provides its partners and companies-in-residence, John Morriss, a seasoned medtech R&D professional, joins us as director of our Invention Acceleration program.
A former Stanford Biodesign Fellow and Fogarty Institute entrepreneur, 32-year-old Holly Rockweiler has already had remarkable accomplishments early in her career, fluently moving her startup to the next level.
Most notably, Holly has parlayed Madorra’s impressive study results into securing funding, including winning several pitching competitions, despite the chronically challenging medtech fundraising environment.
Fogarty Institute graduate InterVene, a startup that has developed a minimally invasive device for the treatment of venous disease in the legs, has treated the 10th patient in their ongoing, multi-center, feasibility study in New Zealand and Australia.
Learning to build a healthy company culture; becoming an empathetic, yet effective, leader; and giving back to individuals and the industry are just a few of the important skill sets learned by the Ferolyn Fellows. They are also key traits embodied by the program’s namesake, Ferolyn Powell.
When a cardiovascular intervention is called for, a less-invasive solution is always preferred – which is why percutaneous procedures, such as transcatheter aortic valve replacement (TAVR) and endovascular aneurysm repair (EVAR) are on the rise.
But this trend hasn’t been without its drawbacks, as cardiologists and surgeons are now faced with the challenge of closing relatively large femoral access sites – ranging from three to eight millimeters in size – that are required to conduct these procedures.
The Fogarty Institute prides itself on hiring staff members who are as innovative and impressive as its companies-in-residence. That means that not only must they have the skill sets for the specific job, but they also come with a well-rounded background and passion for the industry and the startup environment, thus allowing them to inspire our colleagues and mentor our entrepreneurs.
The strength of a board comes from the diverse experiences of its members, their passion for the mission and their ability to provide sage advice. Lewis (Lew) Wexler, MD, one of the Fogarty Institute’s inaugural members, joined the board as the organization’s mission and structure were still being formed and over the years has been a staunch ally and supporter of its educational approach.
There’s nothing more inspiring than working with interns and feeding off their curiosity and eagerness to learn more about the life sciences industry. That’s why the Lefteroff Fellowship remains one of our favorite programs here at the Institute.
Now in its fifth year, it continues to evolve, thanks to our expanding collaboration with El Camino Hospital physicians,